Price$0.05-0.55 (-91.73%)
2025-12-302026-04-06
News · 26 weeks130%
2025-12-142026-06-07
Mix290d
- SEC Filings1(50%)
- Other1(50%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by IO Biotech Inc.SCHEDULE 13G/A - IO Biotech, Inc. (0001865494) (Subject)
- SECIO Biotech Inc. filed SEC Form 8-K: Bankruptcy or Receivership8-K - IO Biotech, Inc. (0001865494) (Filer)
- SECSEC Form 8-K filed by IO Biotech Inc.8-K - IO Biotech, Inc. (0001865494) (Filer)
- SECSEC Form SCHEDULE 13G filed by IO Biotech Inc.SCHEDULE 13G - IO Biotech, Inc. (0001865494) (Subject)
- SECSEC Form 8-K filed by IO Biotech Inc.8-K - IO Biotech, Inc. (0001865494) (Filer)
- PRIO Biotech Provides Corporate UpdateRaymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James & Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives. The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company's workforce, to reduce operating expenses while the company explores strategic al
- ANALYSTIO Biotech downgraded by Piper Sandler with a new price targetPiper Sandler downgraded IO Biotech from Overweight to Neutral and set a new price target of $0.50
- SECAmendment: SEC Form SCHEDULE 13D/A filed by IO Biotech Inc.SCHEDULE 13D/A - IO Biotech, Inc. (0001865494) (Subject)
- SECSEC Form 8-K filed by IO Biotech Inc.8-K - IO Biotech, Inc. (0001865494) (Filer)
- PRIO Biotech Announces Exploration of Strategic AlternativesNEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that the company intends to explore a range of strategic alternatives to maximize stockholder value. Strategic alternatives that may be evaluated include, but are not limited to, a merger, a business combination, a sale of assets or other strategic transaction or a liquidation and dissolution. The company is also evaluating a further reduction-in-force and other efforts to significantly reduce the company's operating expenses while the company explores a range of strategic alternative
- ANALYSTIO Biotech downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded IO Biotech from Equal-Weight to Underweight and set a new price target of $0.36
- SECSEC Form 8-K filed by IO Biotech Inc.8-K - IO Biotech, Inc. (0001865494) (Filer)
- PRIO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature CommunicationsFindings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanomaFive-year analysis of median progression free survival was 25.5 monthsThese results reinforce the potential of immune-modulatory vaccination NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the publication in Nature Communications of the long-term clinical and immunological outcomes from MM1636, the Phase 1/2 trial evaluating the investigational peptide vaccine IO102-IO103 targeting both
- PRIO Biotech Announces Participation in Upcoming December Investor ConferencesNEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the Company's participation in the 8th Annual Evercore Healthcare Conference taking place in Florida on December 2, 2025, as well as the Piper Sandler Annual Healthcare Conference in New York on December 3, 2025. Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO, will participate in a fireside chat and host one-on-one meetings with investors at each conference. Event: 8th Annual Evercore Healthcare ConferenceLocation: Coral Gables, FloridaFireside chat: Tuesday, December 2
- SECSEC Form 8-K filed by IO Biotech Inc.8-K - IO Biotech, Inc. (0001865494) (Filer)
- PRRemeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting ForAUSTIN, Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As late-stage biotech pipelines mature, fair-value remeasurements under U.S. Generally Accepted Accounting Principles (GAAP) are emerging as critical indicators of tangible scientific and commercial progress. These revaluations provide a financial bridge between laboratory breakthroughs and shareholder value, offering investors a clearer picture of how innovation becomes measurable enterprise worth. Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile) exemplifies this shift as the company prepares for a significant fair-value remeasurement of its 45% stake in joint venture (JV) entity GMP Bio, driven by a new ind
- SECSEC Form 8-K filed by IO Biotech Inc.8-K - IO Biotech, Inc. (0001865494) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by IO Biotech Inc.SCHEDULE 13G/A - IO Biotech, Inc. (0001865494) (Subject)
- SECSEC Form 10-Q filed by IO Biotech Inc.10-Q - IO Biotech, Inc. (0001865494) (Filer)
- SECIO Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - IO Biotech, Inc. (0001865494) (Filer)
- PRIO Biotech Reports Third Quarter 2025 Financial Results and Provides Business HighlightsTopline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, although statistical significance on the PFS primary endpoint was narrowly missedMeeting scheduled with FDA in December to align on the design of a potential new Phase 3 registrational trial for IO102-IO103 in patients with advanced melanomaPre-clinical data for additional T-win platform pipeline candidates IO112 targeting arginase 1 and IO170 targeting transforming growth factor (TGF)-β were presented at the Society for Immunotherapy of Cancer's (SITC) Annual MeetingEnded the third quarter with appro
- PRIO Biotech Announces Participation in Upcoming Investor ConferencesNEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that members of its senior management team will participate in the following upcoming investor conferences: Event: Jefferies Global Healthcare ConferenceLocation: LondonPresentation: Tuesday, November 18, 2025, at 3:00 PM GMT Presenter: Mai-Britt Zocca, PhD, President & CEOWebcast Link: https://wsw.com/webcast/jeff332/iobt/1846538 Event: Piper Sandler 36th Annual Healthcare ConferenceLocation: New YorkFireside chat: Wednesday, December 3, 2025, at 3:00 pm ETPresenter: Mai-Britt Zocc
- PRIO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Pre-clinical data for IO Biotech's next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted modulation of immunosuppressive myeloid cells, including tumor-associated macrophages (TAMs)Pre-clinical data for IO Biotech's additional T-win vaccine candidate, IO170 targeting Transforming Growth Factor (TGF)-β, demonstrates induction of immune responses that could inhibit tumor growth and reduce lung metastasisData presented at the Society for Immunotherapy of Cancer's Annual Meeting NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage bioph
- PRNanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in OncologyNetworkNewsWire Editorial Coverage NEW YORK, Oct. 27, 2025 /PRNewswire/ -- The global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce toxicity and improve patient outcomes. Traditional oral or IV drugs often face poor bioavailability and limited tumor targeting — a major bottleneck in cancer treatment success. Recent breakthroughs in nanomedicine are making headlines, as the FDA and global regulatory bodies increasingly endorse nanocarrier-based delivery for complex drugs. This surge underscores a larger industry trend: the race to improve how drugs reach and act within the body. Oncotelic Therapeutics Inc.'s (OTCQB:OTLC) (profile) Decip
- PRIO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS) primary endpoint for statistical significance Improvement in PFS favored the combination across virtually all subgroups, notably in patients with PD-L1-negative tumors, BRAFV600-mutated tumors, and elevated LDH, without adding any systemic toxicity compared to pembrolizumab alone Final data from the Phase 2 basket trial in lung and head & neck cancers also presented NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical com
IOBT FAQ
7 questionsWhat does IO Biotech Inc. do?
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops disruptive immune modulating anti-cancer therapies in Denmark. The company's lead product candidate, IO102-IO103, is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death ligand (PD-L1). It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. IO Biotech, Inc. was incorporated in 2021 and is based in Copenhagen, Denmark.Where does IOBT stock trade?
IO Biotech Inc. (IOBT) is listed on NASDAQ.What sector and industry is IOBT in?
IO Biotech Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did IO Biotech Inc. go public?
IO Biotech Inc. (IOBT) completed its IPO in 2021.What are analysts saying about IOBT?
IO Biotech Inc. has had 7 recent analyst actions on file. The most recent action was from Piper Sandler: Neutral with a $50.00 price target on 2026-01-26.What companies are similar to IOBT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IOBT side-by-side with any of them on Quantisnow.How can I track IOBT on Quantisnow?
Quantisnow aggregates IO Biotech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IOBT to receive live email and push alerts on every new disclosure.